Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jorge A. Ross Terres"'
Autor:
Jacob P. Thyssen, Jorge A. Ross Terres, Evangeline J. Pierce, Meghan A. Feely, Jonathan I. Silverberg
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 1, Pp 5-18 (2023)
Abstract Atopic dermatitis (AD) has been associated with cardiovascular disease (CVD). A better understanding of CVD risk factors in AD populations may help dermatologists better counsel their patients regarding potential risks and treatment choices.
Externí odkaz:
https://doaj.org/article/4830091a8a31466eb6ea48fc97f35c6d
Autor:
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-9 (2022)
Abstract Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical tria
Externí odkaz:
https://doaj.org/article/4d118c8e78e2474c874245f67f839d0d
Autor:
Richard A Furie, Sander W Tas, Edward M Vital, Ana Malvar, Thomas Schindler, Harini Raghu, Cary M Looney, Jorge A Ross Terres, Veronica G Anania, Ashley Mao, Elsa Martins
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/234713c2e081478bb3561224636f5fd9
Autor:
Thomas Dörner, Yoshiya Tanaka, Ernst R Dow, Alisa E Koch, Maria Silk, Jorge A Ross Terres, Jonathan T Sims, Zhe Sun, Inmaculada de la Torre, Michelle Petri
Publikováno v:
Annals of the Rheumatic Diseases. 81:1267-1272
ObjectivesTo elucidate the mechanism of action of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, and describe immunological pathways related to disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy
Autor:
Natalia, Bello, Julie A, Birt, Jennifer, Workman, Xian, Zhou, Jorge A, Ross-Terres, Michelle, Petri
Publikováno v:
Advances in Therapy. 39:3131-3145
Musculoskeletal (MSK) symptoms, including arthritis and arthralgia, are common manifestations of systemic lupus erythematosus (SLE); definitions of activity patterns in SLE differ across studies. This study described clinical characteristics and trea
Autor:
Raj Punwaney, Sandra V. Navarra, Amy Pierce, Saira Z Sheikh, Ricardo Acayaba de Toledo, Josep Ordi Ros, Roger A. Levy, Ignacio García-De La Torre, Jorge Alfonso Ross Terres, James Cheng-Chung Wei, David M. Roth, Morton Scheinberg, Beulah Ji, Mercedes A. García, Julia Harris, Damon Bass, Alireza Nami, Tamara Mucenic, D. Tegzova, Kevin S. Thorneloe, Kathleen Maksimowicz-McKinnon, Mauricio R Abello Banfi, William Stohl, Carlos Abud-Mendoza
Publikováno v:
The Lancet Rheumatology. 3:e122-e130
Summary Background Belimumab is approved for the treatment of active systemic lupus erythematosus (SLE). Although clinical trials showed a favourable benefit–risk profile, numerical differences in the incidence of mortality and adverse events of sp
Autor:
Andreas Wollenberg, James Piercy, Peter A. Lio, Amy M. DeLozier, Maria Jose Rueda, Carle Paul, Jorge A. Ross Terres, Gary Milligan, Jacob P. Thyssen, Peter Anderson, Evangeline Pierce, Jonathan I. Silverberg
Publikováno v:
Journal of Drugs in Dermatology. 19:943-948
Background Atopic dermatitis (AD) has a negative impact on patientsr quality of life (QoL). Objective To report the impact of specific AD lesion locations on QoL in adult patients with AD using real-world data. Methods The Adelphi US Disease Specific
Autor:
Marcella Paglione, Jorge Alfonso Ross Terres, Alan W. McMahon, Robert N. Willette, John R. Sedor, Patrick H. Nachman, M. Claire Holland, J. Charles Jennette, Michelle A. Hladunewich, Sue Vallow, Richard A. Lafayette, Feng Gao, Kevin S. Thorneloe, Debbie S. Gipson, Dennis L. Sprecher, Brad H. Rovin, Sean J. Barbour
Publikováno v:
Kidney International Reports
Introduction Idiopathic focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. In preclinical models and biopsies of human FSGS kidneys, p38 mitogen-activated protein kinase (MAPK) has demonstr
Autor:
Dominique Ibañez, Jiandong Su, Dafna D. Gladman, Jorge Alfonso Ross Terres, Murray B. Urowitz, Sandra Iczkovitz, Amyn Sayani, Sara Mursleen
Publikováno v:
The Journal of Rheumatology. 48:67-73
Objective.To examine the role of disease activity on organ damage over 5 years in patients with active systemic lupus erythematosus (SLE) despite standard of care.Methods.This analysis of the University of Toronto Lupus Clinic cohort assessed organ d
Autor:
N. Bello, Patrick Durez, Gerd R Burmester, Josef S Smolen, Jorge A. Ross Terres, Maher Issa, Kevin L. Winthrop, Walter Deberdt, Peter C. Taylor, Tsutomu Takeuchi
Publikováno v:
Annals of the rheumatic diseases, Vol. 81, no.3, p. 335-343 (2022)
ObjectiveTo report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA).MethodsTreatment-emergent adverse events are summarised from an integra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5274acc07071a28653d139a066957966
https://hdl.handle.net/2078.1/261375
https://hdl.handle.net/2078.1/261375